Compugen ((CGEN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Compugen Ltd is currently recruiting participants for a clinical trial titled An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC). The study aims to assess whether COM701, an experimental antibody, can delay the progression of ovarian cancer and its safety profile.
The trial is testing COM701, administered intravenously every three weeks, as both a standalone treatment and in combination with other anti-cancer drugs. The primary goal is to determine if COM701 can slow or stop cancer progression and delay the need for new treatments.
This interventional study uses a randomized, parallel, triple-masked design. Participants are randomly assigned to receive either COM701 or a placebo, with a 67% chance of receiving the experimental drug. The primary purpose is treatment, and the study includes regular safety and efficacy reviews by a data monitoring committee.
The study began on July 22, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on the same start date, indicating active recruitment and ongoing study activities.
The successful development of COM701 could positively impact Compugen’s stock performance by enhancing investor confidence in its pipeline. This trial’s progress is crucial in the competitive oncology market, where innovative treatments are highly sought after.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.